GlassScriptPhysician profile
Jessica Edwards
NPI 1205011087
$10,833.85
in general payments reported to CMS, 2019-2025
21 companies · $3,279 in 2025
The $3,279 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $711 · 2021: $919 · 2022: $661 · 2023: $1,470 · 2024: $2,559 · 2025: $3,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,167 · Travel and Lodging: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,166.77 |
| Travel and Lodging | $141.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,784.83 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $2,426.64 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,141.93 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $797.59 | 2021-2025 | Caplyta |
| Tris Pharma INC | $541.87 | 2023-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Allergan, INC. | $466.29 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $417.27 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $376.34 | 2023-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $363.44 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $261.50 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $248.82 | 2024-2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $245.09 | 2020-2025 | Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $236.09 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $153.31 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $125.13 | 2024-2025 | Loreev Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $100.00 | 2024 | Zurzuvae |
| Neos Therapeutics, LP | $37.14 | 2024-2025 | Adzenys Xr-Odt |
| Lundbeck LLC | $35.94 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $33.72 | 2024 | |
| Indivior INC. | $23.03 | 2024 | Perseris |
| Acadia Pharmaceuticals INC | $17.88 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.